ACADIA Pharmaceuticals is trading at $23.36, down 9.8%, after remlifanserin narrowly missed statistical significance on the Phase 2 RADIANT primary endpoint (p=0.0603). - The key secondary endpoint was nominally significant (p=0.0077), but the 30 mg dose showed minimal improvement. - Acadia plans to continue Phase 3 development primarily with the 60 mg dose. - Results were released September 24, 2026, before an 8:00 a.m. Eastern conference call; the decline was company-specific despite biotechnology sector strength and broader market weakness.